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Introduction
The principal yardstick to measure the efficiency of can-
cer control is the statistics of five-year relative survivals.
These statistics show the percent of people, who survived
five years after diagnosis and are “statistically” cured
from cancer [1, 2].
In Europe of the period 1978-1989, only 1/3 of wo-
men suffering from ovarian cancer survived 5 years after
the first diagnosis. A small improvement in the survivals
was found in women aged under 65 in Denmark, the Ne-
therlands, and Finland [3, 4]. In the United States of the
period 1989-1996, the five-year relative survivals in ova-
rian cancer reached 50.4% [5]. Better utilization of the
new methods for early detection (markers, USG per va-
ginam) and more efficient surgical and chemical treat-
ment are usually identified as the reason of these rates
[3].
The aim of this work was to compare the five-year
relative survivals among ovarian cancer patients in War-
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A i m. The statistics of five-year survivals are the principal yardsticks used in evaluating the efficiency of cancer control. The
aim of this work is to compare the five-year relative survivals of ovarian cancer patients in Warsaw in the periods 1983-1984
and 1993-1994.
M a t e r i a l  a n d  m e t h o d s. The study included 283 women with ovarian cancer in the period 1983-1984 and 316 ovarian
cancer patients registered by the Warsaw Cancer Registry in the years 1993-1994. The material used for the calculations of the
five-year relative survivals was collected and processed according to T. Hakulinen's method.
Re s u l t s. A statistically insignificant increase in the five-year relative survival rates was found in the period 1983-1994. At the
same time, a statistically significant increase in the five-year survivals of ovarian patients who received surgical and chemical
treatment (from 6.9 to 34.3%; t = 4.38; p<0.05) was observed.
C o n c l u s i o n. The five-year relative survivals of Warsaw women with ovarian cancer were low in the years 1993-1994, signi-
ficantly lower than in a comparable time in the United States.
Porównanie pi´cioletnich prze˝yç wzgl´dnych chorych na raka jajnika
w Warszawie w latach 1983-84 i 1993-94. Doniesienie wst´pne
Statystyka prze˝yç pi´cioletnich jest podstawowym miernikiem oceny efektywnoÊci w zwalczaniu nowotworów. Celem
pracy by∏o porównanie 5-letnich prze˝yç wzgl´dnych chorych na raka jajnika w Warszawie w latach 1983-1984
i 1993-1994.
Materia∏ badany stanowi∏o 283 kobiet chorych na raka jajnika w latach 1983-1984 i 316 kobiet w latach 1993-1994,
zarejestrowanych w Warszawskim Rejestrze Nowotworów. Materia∏ do obliczania 5-letnich prze˝yç wzgl´dnych zebra-
no i opracowano wg metody T. Hakulinena. W latach 1983-1994 stwierdzono nieznamienny statystycznie wzrost pi´ciolet-
nich prze˝yç wzgl´dnych. JednoczeÊnie stwierdzono istotne statystycznie zwi´kszenie prze˝yç 5-letnich chorych na raka jaj-
nika, leczonych chirurgicznie i chemicznie (z 6,9% do 34,3%; t = 4,38; p<0,05). U kobiet chorych na nowotwory z∏oÊliwe
jajnika w Warszawie w latach 1993-94 5-letnie prze˝ycia wzgl´dne by∏y istotnie ni˝sze ni˝ w porównywalnym okresie w USA.
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saw in the periods 1983-1984 and 1993-1994, considering
age, stage and treatment method.
Material and methods
The information source used were cancer reporting cards (MzN1
and MzN-1a) submitted to the Warsaw Cancer Registry by he-
alth centers and other data extracted from medical documenta-
tion, and information obtained from the Census Office.
The material comprised 296 and 348 ovarian cancer cases
registered, respectively in the periods 1983-1984 and 1993-1994.
For methodological reasons, calculations of the five-year relati-
ve survivals used 283 cases registered in the years 1983-1984
(243 were histologically confirmed) and 316 cases registered in
the years 1993-1994 (278 histologically confirmed).
During the study periods, 4 and 17 cases were lost from si-
ght respectively.
The following disease advancement (the classification of di-
sease advancement stages was possibly in cases registered over
the years 1993-1994 on cancer reporting cards MzN-1a) were di-
stinguished:
– Local – with no metastasis to lymph nodes,
– Regional – with metastasis to regional lymph nodes,
– Generalised – with metastasis to internal organs,
– Unspecified – cases outside the present categories.
The material used for calculations of the survival rates was
collected and processed according to the method of Hakulinen
[6]. The relative survivals were calculated as a quotient of the
probabilities of survival among cancer patients (observed survi-
vals) and the estimated probability of survival among women
in the general population, the same age, and place of living
(expected survivals). The survivals expected for the individual
age groups in the general population were calculated from Life
Tables of Poland [7, 8].
The five-year relative survivals were a cumulative probabi-
lity of surviving, calculated as a product of the probabilities of su-
rviving another five years.
Results
Although the study period saw an increase of the five-
-year relative survivals in relation to the total relative su-
rvivals and in the three age groups under study, it was
not statistically significant (Table I).
Table I. Relative five-year survivals among ovarian cancer patients
(ICD 183) by age.
Warsaw 1983-1984 and 1993-1994
Age groups 1983-1984 1993-1994
Total 35.2% (3.1%)* 39.2% (3.0%)
0-49 years 53.5% (6.0%) 60.5% (5.4%)
50-64 years 32.6% (4.4%) 34.2% (4.4%)
65 years and over 17.8% (5.2%) 24.3% (5.0%)
*)  Standard deviation is given in brackets
No statistically significant differences were found in
the five-year relative survivals in the study periods, related
to the histological type.
A statistically significant increase in the five-year
relative survival rate in the periods 1983-1984 and 1993-
-1994 was found in the group of people treated surgically
and chemically (respectively, 6.9% and 34.3%) (Table II).
The five-year relative survival rates among ovarian
cancer patients were found lower in the Warsaw popula-
tion than in the US population with all the disease advan-
cement stages (Table III).
Table III. Relative five-year survivals among ovarian cancer patients
(ICD 183) by advancement stage. Warsaw 1993-1994 and 1989-1996
Disease stage of advancement Warsaw 1993-1994 USA 1989-1996
Local 72.7% (45.6%)# 94.6% (25%)
Regional 20.7% (19.3%) 79.0% (9%)
Generalised 1.1% (34.5%) 28.2% (60%)
Unspecified 0% (0.6%) 28.0% (6%)
Total 39.2% 50.4%
# The percent proportion of each advancement stage is given in brackets
Discussion
The study used five-year relative survivals, which rule out
the effect of the age structure and, by this, allow compari-
sons between different populations.
The study was based on data from a population-ba-
sed registry, which ruled out the selection-related error,
although the five-year survival rates may potentially be
underestimated because of a larger proportion of per-
sons lost from sight in the years 1993-1994.
The normal distribution of the five-year relative su-
rvival rates allowed the application of the t-Student test.
Despite the fact that new methods for the early de-
tection of ovarian cancer were introduced in the study
period and modifications in the chemical treatment me-
thods, no significant increase in the five-year relative su-
rvival rates were found in the Warsaw population suffe-
ring from ovarian cancer.
The discovered statistically significant improvement
of the five-year relative survival rates found in ovarian
cancer patients treated with surgical and chemical me-
thods should be analyzed carefully because objective re-
asons (no data on the disease stage of advancement in
cancer reporting cards submitted in the years 1983-1984)
ruled out analyzing the stages of advancement.
Ovarian cancer is the gynecologic malignancy asso-
ciated with the highest death rate. No modality has been
shown as an effective screening method for this cancer.
Women with a family history of ovarian cancer may bene-
Table II. Relative five-year survivals among ovarian cancer patients
(ICD 183) by treatment methods. Warsaw 1983-1984 and 1993-1994
Treatment method 1983-1984 1993-1994
Surgery 52.4% (9.2%) 76.1% (10.1%)
Surgery and irradiation 78.6% (5.6%) 86.9% (6.8%)
Surgery, irradiation, chemotherapy 55.8% (10.3%) 55.7% (7.6%)
Surgery and chemotherapy 6.9 % (3.9%)a 34.3% (4.9%)a
Chemotherapy 0.0% 17.5% (11.4%)
Irradiation, chemotherapy 0.0% 0.0%
Symptomatic 2.7% (2.7%) 1.5% (1.5%)
a) statistically significant difference t=4.38; p<0.05
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fit from combined modality screening; prophylactic oro-
phorectomy should be offered to those with hereditary
ovarian cancer syndromes [9].
In Europe during the period 1978-1989 inter country
differences in survival for ovarian cancers narrowed and
improved probably in relation to the cisplatin-based treat-
ment protocols [10].
The SEER study found that age was an indepen-
dent prognostic factor in ovarian cancer and that decrease
in survival rates was also observed within stage [11].
The five-year relative survival rates in the United
States are clearly higher than in Warsaw, especially in
the regional and generalized stage [5].
Warsaw has a higher rate of early and regional stages
than the United States, although the five-year relative
survival rates in the US are by 21.9% higher in patients
with local advancement stage, by 58.3%, in patients with
regional advancement stage, and by 27.1% in patients
with the advanced clinical stage of cancer. This may sug-
gest either wrong classification of disease advancement
stages (stage migration) resulting from insufficient dia-
gnosis, or it may suggest lower access to professional tre-
atment under Polish realities [12].
Conclusions
1. The periods of 1983-94 in Warsaw saw a statistically in-
significant increase of the five-year relative survival
rates among ovarian cancer patients (from 35.2 to
39.2%).
2. A statistically significant increase in the five-year rela-
tive survival rates was found in the study period among
persons receiving surgical and chemical treatment
(from 6.9 to 34.3%).
3. Lower rates of the five-year relative survivals were fo-
und in all the disease advancement stages in Warsaw
than in the USA.
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